Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Orphan receptor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Orphan receptor. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2020-001167-93 Sponsor Protocol Number: Sobi.IMMUNO-101 Start Date*: 2020-03-27
    Sponsor Name:SWEDISH ORPHAN BIOVITRUM AB (PUBL)
    Full Title: A phase 2/3, randomized, open-label, parallel group, 3-arm, multicenter study investigating the efficacy and safety of intravenous administrations of emapalumab, an anti-interferon gamma (anti-IFN¿...
    Medical condition: SARS-CoV-2 infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-005402-65 Sponsor Protocol Number: IIBSP-ANA-2013-163 Start Date*: 2015-01-19
    Sponsor Name:Institut de Recerca HSCSP
    Full Title: Efficacy and safety of anakinra (antagonist of the interleukin-1 receptor) in the treatment of periarticular inflammation in patients refractory to NSAID and / or steroids
    Medical condition: Inflammation in periarticular structures in patients refractory to NSAIDs and / or corticosteroids.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004089-16 Sponsor Protocol Number: 1541-128 Start Date*: 2013-04-03
    Sponsor Name:Universitätsklinik für Innere Medizin III, Klinische Abteilung für Rheumatologie, Medizinische Universität Wien
    Full Title: The effect of the interleukin-1 receptor antagonist Anakinra in patients with osteoarthritis of the hand: The AHOA (Anakinra in hand osteoarthritis) pilot study
    Medical condition: osteoarthritis of the hand
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003725-42 Sponsor Protocol Number: R121178 Start Date*: 2018-03-23
    Sponsor Name:University of Manchester
    Full Title: Does Interleukin-1 Receptor Antagonist Improve Outcome following aneurysmal Subarachnoid Haemorrhage (aSAH)? A Phase III trial
    Medical condition: subarachnoid haemorrhage
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022117 - Injury, poisoning and procedural complications 10042316 Subarachnoid haemorrhage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-003683-28 Sponsor Protocol Number: SI003-001 Start Date*: 2022-07-28
    Sponsor Name:SelectImmune Pharma AB
    Full Title: Kineret for the treatment of Bladder Pain Syndrome (BPS). Randomized, double-blind, cross-over, phase II trial.
    Medical condition: Patients diagnosed with Bladder Pain Syndrome (BPS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004974-16 Sponsor Protocol Number: IL1ra03 Start Date*: 2018-11-08
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
    Full Title: DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMISED CLINICAL DOSE-RANGING STUDY TREATING MODERATE-SEVERE TRAUMATIC BRAIN INJURY PATIENTS WITH RECOMBINANT HUMAN INTERLEUKIN 1 RECEPTOR ANTAGONIST.
    Medical condition: We wish to study the drug Kineret in patients suffering from moderate-to-severe traumatic brain injury
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004863 10060690 Traumatic brain injury LLT
    20.1 10029205 - Nervous system disorders 10051288 Central nervous system inflammation PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000249-38 Sponsor Protocol Number: R118439 Start Date*: 2019-01-25
    Sponsor Name:University of Manchester
    Full Title: Phase II trial of interleukin-1 receptor antagonist in intracerebral haemorrhage: BLOcking the Cytokine IL-1 in ICH
    Medical condition: intracerebral haemorrhage
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10022753 Intracerebral haemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2013-004291-35 Sponsor Protocol Number: CACZ885N2301 Start Date*: 2014-05-16
    Sponsor Name:Novartis Farma SpA
    Full Title: A randomized, double-blind, placebo controlled study of canakinumab in patients with Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF), with subsequent randomized withdrawal/ dosing frequency redu...
    Medical condition: Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10010331 - Congenital, familial and genetic disorders 10067783 Tumor necrosis factor receptor-associated periodic syndrome LLT
    16.1 10010331 - Congenital, familial and genetic disorders 10016207 Familial mediterranean fever PT
    16.1 10010331 - Congenital, familial and genetic disorders 10072010 Hyper IgD syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed) IE (Completed) DE (Completed) BE (Completed) HU (Completed) NL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2017-003028-59 Sponsor Protocol Number: NL62684.091.17 Start Date*: 2018-06-06
    Sponsor Name:Radboud University Medical Centre
    Full Title: Treatment with Recombinant human Interleukin 1 receptor antagonist (Anakinra) in patients with Anaplastic Thyroid Cancer: a proof of concept study
    Medical condition: Anaplastic Thyroid Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002165-39 Sponsor Protocol Number: P04887 Start Date*: 2006-11-30
    Sponsor Name:Schering Plough Research Institute, a division of Schering Corporation
    Full Title: Study of the Efficacy and Safety of SCH486757 in Subjects With Chronic Idiopathic Cough
    Medical condition: Chronic Idiopathic Cough
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-002611-96 Sponsor Protocol Number: ANAK/IL-01 Start Date*: 2014-02-12
    Sponsor Name:Consorci Mar Parc de Salut de Barcelona (Parc de Salut MAR)
    Full Title: Pilot study to determine the efficacy of anakinra (antagonist of interleukin-1 receptor) administered for 3 months in improving inflammatory signs observed by MRI in patients with erosive/inflammat...
    Medical condition: Patients with erosive/inflammatory hand osteoarthritis.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006922-32 Sponsor Protocol Number: HOADO Start Date*: 2009-02-09
    Sponsor Name:RUNMC
    Full Title: Heme oxygenase (HO) activity in humans. Effects of heme arginate (Normosang®) on parameters of HO activity and on adenosine induced vasodilation.
    Medical condition: Normosang treatment will be used to evaluate heme oxygenase induction in healthy subjects. Results will be used for future studies concerning diabetes related cardiovascular disease.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051615 Atherosclerotic cardiovascular disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003114-10 Sponsor Protocol Number: NI-0501-09 Start Date*: 2018-09-06
    Sponsor Name:Swedish Orphan Biovitrum AG
    Full Title: An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess its Efficacy, Safety, Impact on Quality of Life...
    Medical condition: Primary Hemophagocytic Lymphohistiocytosis (pHLH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021428 - Immune system disorders 10071583 Haemophagocytic lymphohistiocytosis PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) IT (Completed) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001757-28 Sponsor Protocol Number: 2013/066st Start Date*: 2013-11-20
    Sponsor Name:Salford Royal NHS Foundation Trust
    Full Title: Does subcutaneous interleukin-1 receptor antagonist reduce inflammation following ischaemic stroke compared to placebo?
    Medical condition: Ischaemic stroke
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000300-42 Sponsor Protocol Number: 03AR0298 Start Date*: 2013-01-18
    Sponsor Name:National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
    Full Title: A long-term outcome study with the IL-1 receptor antagonist Anakinra/Kineret® in patients with Neonatal onset multisystem inflammatory disease (Nomid/Cinca syndrome)
    Medical condition: neonatal onset multisystem inflammatory disease (NOMID/CINCA)
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-000137-17 Sponsor Protocol Number: BA3021-001 Start Date*: 2022-09-27
    Sponsor Name:BioAtla
    Full Title: A Phase 1/2 Dose Escalation and Dose Expansion Study of Ozuriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors
    Medical condition: Advanced solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) GR (Completed) IT (Prematurely Ended) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001855-35 Sponsor Protocol Number: Start Date*: 2011-08-09
    Sponsor Name:Salford Royal NHS Foundation Trust
    Full Title: Does subcutaneous interleukin-1 receptor antagonist reduce inflammation following subarachnoid haemorrhage?
    Medical condition: Subarachnoid haemorrhage
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10042316 Subarachnoid haemorrhage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-003600-23 Sponsor Protocol Number: APRICOT Start Date*: 2016-04-01
    Sponsor Name:Guy's and St Thomas NHS Foundation Trust
    Full Title: Treatment of Pustular Psoriasis with the IL-1 receptor antagonist anakinra: a randomised, placebo controlled trial and associated mechanistic studies
    Medical condition: Acral Pustular Psoriasis, specifically but not limited to Palmo-Plantar Pustulosis will be the target population for therapeutic intervention with Anakinra in this study.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037575 Pustular psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-003194-22 Sponsor Protocol Number: APHP200009 Start Date*: Information not available in EudraCT
    Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP)
    Full Title: A RANDOMIZED PHASE III MULTICENTER TRIAL COMPARING THE EFFICACY AND SAFETY OF ANAKINRA VERSUS INTRAVENOUS IMMUNOGLOBULIN (IVIG) RETREATMENT, IN PATIENTS WITH KAWASAKI DISEASE WHO FAILED TO RESPOND ...
    Medical condition: Anakinra treatment is expected to reduce the early and long-term mortality of patients with Kawasaki Disease (KD), by a rapid and sustained effect on vascular inflammation.
    Disease:
    Population Age: Infants and toddlers, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003472-13 Sponsor Protocol Number: MYTH-1 Start Date*: 2019-10-31
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Myocarditis Therapy with IL-1 inhibitor (MYTH-1): a double-blind, phase IIa, placebo-controlled, randomized clinical trial to evaluate the efficacy and safety of anakinra in addition to standard of...
    Medical condition: Endomyocardial biopsy proven virus-negative myocarditis with left ventricular ejection fraction lower than 55%.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10007541 - Cardiac disorders 10064539 Autoimmune myocarditis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 07 10:05:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA